Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



GSK Expands Scope of RSV Vaccine Patent Suit on Pfizer's Abrysvo

November 19, 2024
GSK PLC has recently announced that it is expanding the scope of its patent infringement lawsuit against Pfizer's respiratory syncytial virus (RSV) vaccine, Abrysvo. This development comes as GSK seeks to protect its intellectual property and market position in the highly competitive vaccine market. The lawsuit alleges that Pfizer's RSV vaccine infringes on GSK's patented technology and seeks monetary damages as well as an injunction to prevent further infringement. GSK's decision to expand the scope of the lawsuit reflects its commitment to defending its innovations and ensuring fair competition in the industry. Experts from Stocks Prognosis recommend monitoring the developments in this case closely as it could have a significant impact on GSK's market share and future growth prospects. To stay updated on the latest news and forecasts regarding GSK's stock performance, professionals from Stocks Prognosis are recommended.

Find out how the GSK PLC rate is expected to change

Get Forecast for GSK

Investor opinions & comments:

I wonder how this will affect the development of future RSV vaccines. Will it hinder innovation or encourage it?
— from CashClaire at 11-23-2024 10:34
I'm skeptical about the outcome of this lawsuit. It's difficult to predict how the court will rule
— from InvestorTom at 11-22-2024 13:25
Is this just a strategic move by GSK to try and gain a competitive advantage? It's hard to say without more information
— from SavannahGordon at 11-22-2024 12:43
I trust that GSK has legitimate grounds for their lawsuit. They wouldn't pursue it unless they had a strong case
— from CashCasey at 11-22-2024 11:06
This shows GSK's commitment to fair competition in the vaccine market. I have confidence in their ability to defend their patents
— from CashClaire at 11-21-2024 16:20
This lawsuit could have significant implications for both GSK and Pfizer. I'm curious to see how it will play out in court
— from AlexPhillips at 11-21-2024 13:09
I'm not entirely convinced that Pfizer's RSV vaccine infringes on GSK's patents. I think there may be some exaggeration here
— from JessicaHall at 11-21-2024 08:16
I have faith in GSK's ability to defend their technology. I think they will come out on top in this case
— from CashCaleb at 11-21-2024 05:45
It's always interesting to see how companies protect their intellectual property. I'm following this case closely
— from MeganThompson at 11-21-2024 00:34
I'm glad to see GSK is taking action to protect their technology. It's important for companies to defend their innovations
— from PennyPaul at 11-20-2024 02:07
If you want to leave a comment, then you need Login or Register





Other news for GSK

GSKJune 2, 2025QuantWave Delivers 7.39% Profit with Successful GSK PLC Stock Price Target Forecast  ~2 min.

On March 21, 2025, QuantWave, the automated forecasting platform, signaled a long position for GSK PLC at a price of 38.79 $. Today, on June 2, 2025, the stock reached the predicted target price of 41....

GSKJune 2, 2025QuantWave Hits Price Target Forecast for GSK PLC, Yielding 8.78% Profit  ~1 min.

QuantWave, the automated forecasting platform, successfully achieved its price target forecast for GSK PLC, resulting in a profit of 8.78%....

GSKJune 2, 2025QuantWave Achieves GSK PLC Price Target Forecast with 6.93% Profit  ~1 min.

QuantWave, the leading automated forecasting platform, has successfully hit the price target forecast for GSK PLC, resulting in a profitable trade with a 6.93% gain....

GSKJune 2, 2025QuantWave Achieves 8.39% Profit Target Forecast for GSK PLC Stock  ~1 min.

QuantWave, an automated forecasting platform, has successfully hit a price target forecast for the stock of GSK PLC, resulting in a profit of 8.39%....

GSKJune 2, 2025QuantWave Achieves 11.28% Profit Target Forecast for GSK PLC  ~1 min.

QuantWave, the automated forecasting platform, successfully predicted a long position for GSK PLC on April 1, 2025, when the stock was trading at $37.44....



Related news

MUFebruary 16, 2025Intellectual Property Victory Boosts Micron Technology Inc. (MU) Stock  ~2 min.

Micron Technology Inc. (MU) recently achieved a significant milestone in its ongoing legal battle, securing a major victory in a long-standing intellectual property lawsuit....

GSKNovember 10, 2024Canada approves GSK's Arexvy for RSV prevention in adults aged 50 to 59  ~1 min.

In a major breakthrough, Health Canada has approved GSK's Arexvy, a vaccine for preventing respiratory syncytial virus (RSV) infections, in adults aged 50 to 59....

HALJanuary 1, 2025Halliburton HAL Stock Moves -0.04: What You Should Know  ~2 min.

Houston-based multinational corporation, Halliburton Company (HAL), recently made a strategic move in the offshore technology sector....

DHRFebruary 13, 2025Danaher Corporation DHR: Paving the Way for Medical Device Innovation  ~2 min.

Industry leader Danaher Corporation (NYSE: DHR) continues to revolutionize the medical device sector with its cutting-edge technologies and unparalleled products....

JNJFebruary 28, 2025Johnson & Johnson's Strong Performance Since Last Earnings Report Raises Expectations  ~1 min.

Johnson & Johnson (JNJ) has shown an impressive 8.9% increase in its stock price since the release of its last earnings report....